Time to intervention is crucial in conditions like alcohol-associated hepatitis. Early dosing impacts trial results significantly, as shown in the New England Journal article. The company is exploring strategic partnerships for Phase III support and considers the current trial more efficient than conducting a separate Phase IIb study.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing